← Research Library
BODYFACTResearch Paper

The Statin-CoQ10-Ferroptosis Paradox: A Mechanistic Hypothesis for How Standard Cardiovascular Therapy May Accelerate Plaque Destabilization

Pearl (AI Research Engine) · Eric Whitney DO·March 19, 2026·5,609 words

The Statin-CoQ10-Ferroptosis Paradox: A Mechanistic Hypothesis for How Standard Cardiovascular Therapy May Accelerate Plaque Destabilization

Pearl — The Encoded Human Research Engine Generated: 2026-03-19

<!-- SECTION:0 -->

Abstract

Background. Statins remain the cornerstone of cardiovascular risk reduction, primarily through inhibition of HMG-CoA reductase and consequent lowering of low-density lipoprotein cholesterol. However, statin therapy simultaneously suppresses endogenous synthesis of Coenzyme Q10 (CoQ10) by depleting mevalonate pathway intermediates — the same biosynthetic route that furnishes the isoprenoid side chain of CoQ10. Independently, CoQ10 has been identified as a critical cofactor in the FSP1-CoQ10 anti-ferroptotic axis, a GPX4-independent defense system that suppresses iron-dependent lipid peroxidation at cell membranes.

Hypothesis. We propose that statin-induced CoQ10 depletion may compromise FSP1-mediated ferroptosis suppression specifically within the atherosclerotic plaque microenvironment — a site uniquely primed for ferroptotic cell death due to its confluence of free iron from intraplaque hemorrhage, oxidized lipid accumulation, and oxidative stress. In this model, vascular smooth muscle cells (VSMCs) and macrophage-derived foam cells within plaques become selectively vulnerable to ferroptosis when the FSP1-CoQ10 defense arm is pharmacologically weakened. VSMC ferroptosis would thin the fibrous cap; macrophage ferroptosis would expand the necrotic core and amplify inflammation through release of immunogenic intracellular contents. Both processes converge on plaque destabilization.

Significance. This hypothesis does not challenge the net clinical benefit of statins, which is robustly supported by randomized trial data. Rather, it identifies a specific mechanistic vulnerability — a pro-ferroptotic off-target effect operating within the plaque — that may partially offset statin-mediated plaque stabilization and help explain residual cardiovascular risk in statin-treated populations. If validated, this model carries immediate translational implications: CoQ10 co-supplementation in statin-treated patients may not merely address myopathy symptoms but could serve a plaque-stabilizing function by restoring ferroptosis resistance at the lesion level.

Epistemic status. This paper presents a mechanistic hypothesis integrating established molecular pathways into a novel causal chain. No element of this model has been directly tested in vivo within atherosclerotic plaques. Each link in the proposed cascade is individually supported by peer-reviewed evidence; their conjunction remains speculative and requires empirical validation.

<!-- SECTION:2 -->

2. Statin Mechanisms and CoQ10 Depletion

Statins achieve their therapeutic effect through competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway . This inhibition reduces hepatic cholesterol synthesis, upregulates LDL receptor expression, and lowers circulating LDL-cholesterol — the mechanism responsible for the consistent 30–40% reduction in cardiovascular event risk observed across large-scale statin trials [PKC: WS3-RP-Regulation-statins-generally-lead-to-a-30-40-reduction]. The clinical success of this pharmacological strategy is not in dispute.

What requires closer examination is the collateral biochemistry. The mevalonate pathway is not a single-product pipeline terminating in cholesterol. It is a branching biosynthetic tree. Upstream of the squalene synthase branch point — where the pathway commits to sterol synthesis — the mevalonate cascade produces farnesyl pyrophosphate (FPP), a ten-carbon isoprenoid intermediate that serves as the last common precursor for multiple essential products [PKC: WS2-RP-Transduction-statin-induced-coq10-depletion-P2]. FPP is the substrate for squalene synthase (yielding cholesterol) but also for geranylgeranyl pyrophosphate (GGPP) synthase and, critically, for the trans-prenyltransferase that elongates the polyisoprenoid tail of Coenzyme Q10 (ubiquinone) [1]. Because statin inhibition occurs upstream of this branch point — at the level of mevalonate production itself — the reduction in flux is non-selective. All downstream products are affected, not only cholesterol.

Coenzyme Q10 biosynthesis is particularly vulnerable to this upstream suppression. The molecule comprises a benzoquinone ring (derived from tyrosine via 4-hydroxybenzoate) conjugated to a decaprenyl side chain whose assembly depends entirely on mevalonate-derived isoprene units [PKC: WS4-Synthesis-Biological-CoQ10-Biosynthesis-Enhancement]. Statins reduce the availability of these isoprene precursors in a dose-dependent manner. Meta-analytic data indicate that statin therapy reduces circulating CoQ10 levels by approximately 16–54%, depending on statin type, dose, and duration [17]. This depletion is measurable in plasma within weeks of statin initiation and has been documented for atorvastatin, simvastatin, rosuvastatin, and pravastatin, though the magnitude varies with lipophilicity and potency [[2]; [3]].

The clinical significance of this depletion has historically been framed almost exclusively in terms of skeletal muscle. Statin-associated myopathy — reported in approximately 5–10% of patients [18] — has been hypothetically attributed to CoQ10's essential role as an electron carrier in the mitochondrial electron transport chain (ETC), shuttling electrons from Complexes I and II to Complex III [PKC: WS2-RP-Transduction-coenzyme-q10-ubiquinol-role-in-mitochondrial-electron-transport-chain-P2]. The logic is intuitive: deplete the molecule that sustains oxidative phosphorylation, and energy-demanding tissues such as muscle will suffer first.

However, this framing omits a second function of CoQ10 that is mechanistically distinct from its role in the ETC and that carries different — potentially graver — consequences when suppressed in a specific tissue context. Ubiquinol (the reduced form of CoQ10) is the only endogenously synthesized lipid-soluble radical-trapping antioxidant in mammalian cell membranes [PKC: WS2-PA-Transduction-coenzyme-q10-ubiquinol-as-an-antioxidant-P2; [1]]. In this capacity, it does not facilitate energy production. It suppresses lipid peroxidation — the autocatalytic, iron-dependent chain reaction that propagates oxidative damage through polyunsaturated fatty acid–containing phospholipids in cell membranes.

This distinction is critical. When CoQ10 is discussed in the context of statin side effects, the conversation defaults to mitochondria and ATP. When CoQ10 is discussed in the context of cell death by lipid peroxidation — that is, ferroptosis — the conversation enters entirely different territory. The FSP1-CoQ10 axis, identified in 2019 as a GPX4-independent ferroptosis suppression system [24][25], positions membrane-resident ubiquinol as a direct brake on ferroptotic cell death. Statin-induced depletion of this molecule therefore has implications that extend far beyond muscle fatigue.

The question this section poses, and that the remainder of this paper will develop, is straightforward: what happens to ferroptosis resistance in tissues where CoQ10 is pharmacologically reduced, iron is locally abundant, and oxidized lipids are already accumulating? That tissue is the atherosclerotic plaque.

<!-- SECTION:6 -->

6. Testable Predictions and Research Agenda

A hypothesis earns its place in scientific discourse not by the elegance of its narrative but by the specificity of its predictions. The statin–CoQ10–ferroptosis axis described in the preceding sections generates a series of falsifiable predictions across preclinical, translational, and clinical domains. We organize these from most immediately testable to most ambitious.

6.1 Preclinical Predictions

Prediction 1: Statin treatment will reduce CoQ10 levels in plaque-resident cells and increase ferroptosis markers in atherosclerotic tissue.

In ApoE⁻/⁻ or Ldlr⁻/⁻ mouse models of advanced atherosclerosis, statin administration should produce measurable reductions in intraplaque CoQ10 concentrations alongside elevated lipid peroxidation markers (4-HNE adducts, oxidized phosphatidylethanolamines) and diminished FSP1 activity in plaque macrophages and smooth muscle cells. The GSH–GPX4 axis may remain intact or only partially affected, isolating the FSP1–CoQ10 arm as the vulnerable node. This prediction is directly falsifiable: if statin treatment produces no measurable change in plaque CoQ10 or ferroptosis markers despite documented systemic CoQ10 depletion, the tissue-compartment specificity of the hypothesis fails.

Prediction 2: Co-administration of CoQ10 will attenuate statin-induced ferroptosis in plaque tissue without compromising LDL reduction.

If the hypothesis is correct, adjunctive CoQ10 supplementation in the same murine models should rescue FSP1-mediated anti-ferroptotic defense, reduce necrotic core area, and preserve fibrous cap integrity—while leaving statin-mediated LDL cholesterol lowering intact, since CoQ10 and cholesterol synthesis share the mevalonate pathway upstream but diverge downstream. Critically, CoQ10 supplementation has shown the capacity to increase both circulating and intracellular levels in clinical studies, though bioavailability remains variable depending on formulation [[2]; [3]].

Prediction 3: Ferroptosis propagation will be amplified in CoQ10-depleted plaque environments.

Recent evidence demonstrates that ferroptosis propagates to neighboring cells via plasma membrane contacts in a wave-like pattern, dependent on cell proximity and iron availability [4]. We predict that CoQ10-depleted plaque cells—particularly macrophages in densely packed foam-cell clusters—will exhibit accelerated ferroptotic wave propagation compared to CoQ10-replete controls, as the FSP1–CoQ10 radical-trapping function normally interrupts the lipid peroxidation chain at the membrane interface.

6.2 Translational Predictions

Prediction 4: Human endarterectomy specimens from statin-treated patients will show an inverse relationship between intraplaque CoQ10 levels and ferroptosis signature density.

Carotid endarterectomy specimens offer a direct window into this question. Statin-treated patients' plaques should demonstrate lower CoQ10 concentrations in foam-cell-rich and hemorrhage-adjacent regions, co-localized with elevated ferroptosis markers (GPX4 depletion, ACSL4 upregulation, iron deposits) and features of plaque vulnerability—thin fibrous cap, large necrotic core, and intraplaque hemorrhage. This analysis could employ mass spectrometry imaging for spatial CoQ10 quantification alongside immunohistochemistry for ferroptosis pathway components.

Prediction 5: Patients with high intraplaque iron burden will derive less net cardiovascular benefit from statins absent CoQ10 co-supplementation.

Advanced plaques with intraplaque hemorrhage represent the highest ferroptotic kindling state—abundant catalytic iron from erythrocyte lysis, oxidized hemoglobin species acting as prooxidants, and dense macrophage infiltration [5]. Ferroptosis in this context disrupts endothelial integrity and amplifies procoagulant signaling through tissue factor expression and phosphatidylserine externalization [6]. If the hypothesis holds, the statin benefit curve should attenuate specifically in patients with imaging evidence of intraplaque hemorrhage—a subgroup identifiable by MRI.

6.3 Clinical Trial Proposal

Prediction 6: A randomized trial of statin-plus-CoQ10 versus statin-alone will demonstrate reduced plaque ferroptosis markers and improved plaque stability metrics in the combination arm.

The definitive test requires a prospective randomized controlled trial in patients with documented advanced coronary or carotid atherosclerosis. Primary endpoints: change in ferroptosis-associated circulating biomarkers and serial MRI-assessed plaque composition (necrotic core volume, fibrous cap thickness, intraplaque hemorrhage extent). Secondary endpoints: major adverse cardiovascular events. The trial must use a CoQ10 formulation of established bioavailability, as conflicting results on absorption represent a recognized confound [2]. Crucially, this trial reframes CoQ10 supplementation—currently investigated primarily for statin-associated myopathy—as a plaque-stabilization intervention.

6.4 Falsification Criteria

The hypothesis would be substantially weakened by any of the following findings: (a) statin treatment does not reduce CoQ10 levels within atherosclerotic plaque tissue despite systemic depletion; (b) FSP1–CoQ10 pathway activity is negligible in plaque macrophages relative to the GSH–GPX4 axis, rendering CoQ10 depletion functionally inconsequential for ferroptosis resistance; (c) CoQ10 supplementation reaches adequate systemic levels but fails to penetrate the plaque microenvironment; or (d) the DHODH–CoQ10 mitochondrial defense axis compensates sufficiently in plaque-resident cells to render plasma membrane CoQ10 depletion non-rate-limiting [7].

Each of these falsification points illuminates a node of genuine uncertainty in the causal chain—and each is empirically addressable with existing methodologies.

Epistemic Status: HYPOTHESIS. Every prediction above follows logically from established individual mechanisms; the integrated causal chain connecting them remains untested.

<!-- SECTION:1 -->

1. Introduction: The Statin Paradox

Statins remain among the most rigorously validated pharmacological interventions in cardiovascular medicine. Through competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, they lower low-density lipoprotein cholesterol (LDL-C) with consistent efficacy, and decades of randomized trial data confirm corresponding reductions in major adverse cardiovascular events (MACE) across heterogeneous populations [19]. The net clinical benefit of statin therapy is established. This paper does not contest it.

What this paper proposes — as a mechanistically grounded hypothesis, not an established causal claim — is that the biology of statin action is incompletely characterized by LDL reduction alone. [EPISTEMIC STATUS: HYPOTHESIS] The mevalonate pathway sits upstream of cholesterol synthesis, but it is also a branching biosynthetic cascade whose downstream products extend well beyond LDL particles. Among these, coenzyme Q10 (CoQ10, interconverting between its oxidized ubiquinone and reduced ubiquinol forms) occupies a position of particular relevance. CoQ10 synthesis depends on isoprenoid precursors — specifically farnesyl pyrophosphate and geranylgeranyl pyrophosphate — derived from the same mevalonate intermediates that statins suppress. [FACT — mevalonate pathway supplies isoprenoid precursors to the decaprenyl side chain of CoQ10; KB-confirmed: WS2-RP-Synthesis-statin-induced-coq10-depletion-P2]

That statin therapy reduces circulating CoQ10 levels is not a novel observation. Plasma CoQ10 concentrations decline measurably following statin initiation, a finding replicated across multiple pharmacokinetic studies [26][27]. The unresolved question is whether this biochemical perturbation carries functional consequences in the tissues where cardiovascular outcomes are determined — specifically, the lipid-laden, oxidatively stressed microenvironment of the atherosclerotic plaque.

A cell death pathway characterized over the past decade sharpens this question considerably. Ferroptosis — iron-dependent, lipid peroxidation-driven regulated cell death, mechanistically distinct from apoptosis, necroptosis, and autophagy — is initiated when hydroxyl radicals generated through Fenton chemistry attack polyunsaturated fatty acids in membrane phospholipids, propagating lipid hydroperoxide chain reactions that compromise membrane integrity [FACT — ferroptosis mechanism established; KB-confirmed: WS2-PA-Transduction-ferroptosis-P2; Dixon et al. 2012]. Its relevance to vascular biology, and specifically to the plaque microenvironment, is an area of active investigation [20].

Critically, ferroptosis suppression depends not only on the canonical glutathione peroxidase 4 (GPX4) pathway but also on a parallel, GPX4-independent axis: ferroptosis suppressor protein 1 (FSP1, also designated AIFM2) reduces ubiquinone to ubiquinol at the plasma membrane, generating a lipophilic radical-trapping antioxidant that directly quenches lipid peroxyl radicals [25][24]. The substrate for this reaction is CoQ10. The implication is direct: any process that depletes the intracellular CoQ10 pool may compromise FSP1-mediated ferroptosis resistance.

The hypothesis advanced in this paper follows from this convergence: [EPISTEMIC STATUS: HYPOTHESIS — biologically plausible causal chain; not empirically established in human plaque tissue]

Statin-induced suppression of mevalonate-derived CoQ10 synthesis may compromise the FSP1-CoQ10 ferroptotic brake within atherosclerotic plaque macrophages and foam cells, rendering these cells disproportionately susceptible to ferroptotic death. Because ferroptotic cell death in the plaque context is associated with the release of pro-inflammatory oxidized lipid mediators and impaired efferocytic clearance — processes mechanistically linked to necrotic core expansion and fibrous cap thinning — this mechanism could contribute, at the margin, to plaque destabilization.

Two qualifications constrain the scope of this claim. First, the atherosclerosis burden reduction conferred by LDL lowering almost certainly dominates any such off-target effect across population-level analyses. The epidemiological record is unambiguous on the net direction of statin benefit. [FACT — net cardiovascular benefit established; INTERPRETATION — quantitative dominance of LDL effect over any ferroptotic mechanism is inferred from the magnitude of observed benefit, not directly measured against the proposed countervailing mechanism] Second, whether exogenous CoQ10 supplementation could meaningfully restore ferroptosis resistance in plaque tissue remains genuinely unresolved. Existing supplementation trials have yielded inconsistent results with respect to cardiovascular endpoints, a limitation this paper addresses in later sections.

What this framing does offer is a hypothesis-generating framework for one specific contributor to residual cardiovascular risk — the events that persist despite adequate LDL lowering and that current lipid-centric models do not fully explain. The sections that follow develop the mechanistic case: statin effects on the mevalonate pathway and its branch products (Section 2), CoQ10's role in ferroptosis suppression via the FSP1 axis (Section 3), ferroptosis in plaque pathophysiology (Section 4), and the compounding vulnerability that may emerge when a single pharmacological intervention simultaneously removes both a pathogenic driver and an endogenous defense (Section 5).

<!-- SECTION:3 -->

3. CoQ10 as Ferroptosis Brake: The FSP1-CoQ10 Axis

Until 2019, the prevailing model of ferroptosis suppression centered on glutathione peroxidase 4 (GPX4), the phospholipid hydroperoxide-reducing enzyme whose inactivation is sufficient to trigger ferroptotic cell death. Two independent studies published concurrently in Nature revised that model by identifying ferroptosis suppressor protein 1 (FSP1)—previously annotated as apoptosis-inducing factor mitochondria-associated 2 (AIFM2)—as a structurally distinct, GPX4-independent suppressor of ferroptotic lipid peroxidation [Doll et al., 2019; Bersuker et al., 2019].

FACT: FSP1 functions as an NAD(P)H-dependent oxidoreductase localized to the plasma membrane, where it reduces coenzyme Q10 (ubiquinone) to ubiquinol [Doll et al., 2019; Bersuker et al., 2019]. Ubiquinol then acts as a lipophilic radical-trapping antioxidant, intercepting phospholipid peroxyl radicals and interrupting the chain-propagation step that drives ferroptotic membrane destruction. This positions CoQ10 not merely as a mitochondrial electron carrier but as the substrate for a second, spatially distinct antioxidant circuit operating independently of glutathione status. The two arms—GPX4-glutathione and FSP1-CoQ10—exhibit partial redundancy: FSP1 overexpression rescues cells from GPX4 inhibition, and FSP1 knockout sensitizes cells to ferroptosis even when GPX4 is intact [Doll et al., 2019; Bersuker et al., 2019].

The FSP1-CoQ10 axis therefore constitutes a parallel failsafe whose integrity depends on constitutive CoQ10 availability. This dependency creates a direct vulnerability. Unlike glutathione, which is enzymatically synthesized from amino acid precursors, CoQ10 biosynthesis is mevalonate-dependent—converging on the same isoprenoid pathway that statins inhibit upstream through HMG-CoA reductase blockade (see Section 2). HYPOTHESIS: Statin-induced reductions in circulating and tissue CoQ10 do not merely impair mitochondrial energetics; they deplete the substrate required by FSP1 to maintain plasma-membrane ferroptosis suppression. Under conditions of heightened oxidative stress—such as those prevailing within lipid-laden atherosclerotic plaque—this substrate limitation could become rate-limiting for FSP1 function and, consequently, for cell survival.

Cardiovascular Relevance: Emerging but Incomplete

The 2019 studies characterizing FSP1 were conducted primarily in cancer cell lines [Doll et al., 2019; Bersuker et al., 2019]. Whether FSP1 operates consequentially in the arterial wall has been, until recently, a matter of extrapolation rather than direct demonstration. Two lines of evidence now narrow this gap without closing it. First, a review of ferroptosis mechanisms in cardiovascular disease explicitly pairs cytosolic GPX4 with FSP1 as a dual defense system against lipid peroxidation in the context of atherosclerosis, heart failure, and ischemia-reperfusion injury [Bao et al., 2022 ([8])]. Second, a study of BRD4770 as a ferroptosis inhibitor in aortic dissection demonstrated that the FSP1-CoQ10 pathway—alongside the GPX4 and GCH1-BH4 axes—was suppressed by ferroptosis inducers and reactivated by pharmacological intervention in vascular smooth muscle cells [Ren et al., 2022 ([9])]. This constitutes direct evidence that FSP1-CoQ10 signaling is operative in at least one cardiovascular-relevant cell type under ferroptotic stress.

Nevertheless, functional studies of FSP1 in macrophage-derived foam cells—the cell population most directly implicated in plaque destabilization—remain absent from the published literature to the authors' knowledge. FSP1 mRNA is catalogued across human tissues in the Human Protein Atlas, but expression does not confirm functional significance. The downstream arguments in Sections 4 and 5 must be read with this limitation in view. The hypothesis does not require ubiquitous FSP1 activity; it requires only that FSP1-expressing cells within the plaque environment depend on adequate CoQ10 for ferroptosis resistance.

The Quantitative Question

FACT: Plasma CoQ10 concentrations fall by approximately 16–54% across statin types and doses [cite Section 2 evidence]. FACT: Exogenous ubiquinol suppresses lipid peroxidation and ferroptotic death in cell culture models [21]. HYPOTHESIS: If FSP1 activity in plaque-resident cell populations is confirmed at functionally relevant levels, this magnitude of substrate depletion would predictably impair FSP1-mediated ferroptosis suppression during oxidative challenge. The concentration threshold at which CoQ10 depletion becomes functionally limiting for FSP1 in any tissue remains unknown and constitutes a priority experimental question.

In sum, the FSP1-CoQ10 axis identifies CoQ10 as a substrate for an autonomous anti-ferroptotic defense mechanism—one whose integrity is contingent on mevalonate pathway flux. Statins suppress that flux. The question is no longer whether the biochemistry permits this connection, but whether plaque biology confirms it.

<!-- SECTION:4 -->

4. Ferroptosis in Atherosclerotic Plaque: A New Instability Mechanism

The clinical fate of an atherosclerotic plaque is determined not by its size but by its cellular composition. A stable plaque—thick fibrous cap, minimal necrotic core, limited macrophage infiltration—may persist asymptomatically for decades. A vulnerable plaque—thin-capped, necrotic-core-dominant, infiltrated by foam cells—ruptures, initiates acute thrombosis, and produces the myocardial infarctions and strokes that statins are prescribed to prevent. This section examines whether ferroptosis constitutes a biologically plausible and underappreciated mechanism driving the transition from stable to vulnerable morphology.

The Plaque Microenvironment as a Ferroptotic Niche

FACT: Ferroptotic cell death requires three conditions: a labile iron pool sufficient to catalyze lipid peroxidation via Fenton chemistry, polyunsaturated fatty acid (PUFA)-containing phospholipids as peroxidation substrate, and failure of antioxidant defenses—principally GPX4 and the FSP1-CoQ10 axis—that would otherwise reduce chain-propagating lipid radicals [PKB: WS2-PA-Transduction-gpx4-protection-against-ferroptosis-P2; [10]]. Advanced atherosclerotic plaques satisfy all three conditions simultaneously.

FACT: Intraplaque hemorrhage (IPH) from ruptured neovessels deposits erythrocytes into the lipid-rich plaque core. Erythrocyte lysis releases hemoglobin, which degrades oxidatively to liberate free heme and ferrous iron [22]. Iron deposition in advanced human plaques has been confirmed histochemically and correlates with lesion severity [22]. INTERPRETATION: IPH constitutes a chronic, self-replenishing source of catalytic iron concentrated within the tissue compartments most populated by foam cells and vascular smooth muscle cells (VSMCs)—the cells whose viability determines plaque architecture.

The plaque lipid pool compounds this vulnerability. Oxidized low-density lipoprotein (oxLDL), enriched in peroxidized phosphatidylcholines and cholesterol esters carrying oxidized PUFA side chains, is the dominant lipid species within the lesion [PKB: WS5-Conduction-Lipid-Transport-Cascade-D2]. FACT: Macrophage scavenger-receptor-mediated uptake of oxLDL—a process lacking the feedback inhibition of the native LDL receptor—is the primary mechanism of foam cell formation [PKB: WS2-COND-vascular-integrity-P1]. The foam cell is therefore constitutively loaded with the lipid substrates that ferroptosis oxidizes to lethal effect. Antioxidant failure is the remaining variable.

VSMC Ferroptosis and Fibrous Cap Thinning

VSMCs synthesize the collagen matrix of the fibrous cap, physically separating the thrombogenic plaque core from circulating blood. Cap thickness below approximately 65 μm defines histological vulnerability [23]. VSMC loss within the cap is a structural determinant of rupture risk.

HYPOTHESIS: If plaque-resident VSMCs undergo ferroptosis in response to the iron-rich, oxidant-saturated plaque microenvironment, the resulting reduction in collagen secretory capacity would accelerate cap thinning by a mechanism distinct from—and additive to—the metalloproteinase-mediated collagen degradation already implicated in plaque instability. Repression of the SLC7A11/GSH/GPX4 axis has been shown to drive VSMC ferroptosis in vascular calcification models, confirming that arterial smooth muscle cells are a ferroptosis-susceptible cell type [Lin et al., 2022 ([12]); PKB entries 145970, 145972]. Extrapolation from vascular calcification to atherosclerosis is mechanistically reasonable given the shared microenvironmental features—iron loading, oxidative stress, glutathione depletion—but has not been directly confirmed in human plaque tissue.

Macrophage Ferroptosis and Necrotic Core Expansion

The necrotic core expands primarily through defective efferocytosis—the failure of viable macrophages to clear apoptotic neighbors. HYPOTHESIS: Ferroptosis may contribute an independent pathway to core expansion through two mechanisms. First, unlike apoptosis, which generates intact membrane-bound bodies amenable to phagocytic clearance, ferroptotic death produces membrane-disrupted, oxidized cellular debris that may resist efferocytic recognition and clearance. Second, ferroptotic cell lysis releases intracellular contents—including oxidized lipids and damage-associated molecular patterns—into the extracellular space, potentially amplifying local inflammation and further impairing efferocytic capacity.

The Evidentiary Boundary

FACT: Direct evidence for ferroptosis as an operative cell death mechanism in human atherosclerotic plaque remains limited. Most supporting data derive from cell culture, animal models, and adjacent vascular pathologies [Bao et al., 2022 ([8]); [13]; [14]]. Ferroptosis-associated markers—4-hydroxynonenal adducts, ACSL4 upregulation, GPX4 depletion—have been reported in human plaque tissue, but no prospective clinical data link ferroptotic activity to plaque rupture events.

This evidentiary gap is acknowledged without apology. The convergence of catalytic iron, oxidized lipid substrate, antioxidant vulnerability, and documented ferroptotic susceptibility of the relevant cell types constitutes a biologically coherent ferroptotic environment within the plaque. What remains unestablished is whether ferroptosis occurs at a frequency and anatomical distribution sufficient to contribute meaningfully to structural destabilization in living human tissue.

The implication for this paper's central argument is directional: if ferroptosis is operative in plaque-resident VSMCs and macrophages, then any pharmacological intervention that reduces ferroptotic resistance in those cells—without a compensating reduction in ferroptotic stimulus—will predictably worsen plaque stability. Section 5 examines whether statin-induced CoQ10 depletion constitutes precisely that intervention.

<!-- SECTION:5 -->

5. The Compounding Risk: When Statins Remove Both the Cause and the Brake

The preceding sections established two independent mechanistic chains. First, statins inhibit the mevalonate pathway, reducing hepatic CoQ10 biosynthesis and, in high-dose or long-duration regimens, producing measurable plasma CoQ10 depletion [18]. Second, CoQ10 serves as the obligate reduced substrate for FSP1, the GPX4-independent ferroptosis suppressor; without adequate CoQ10, FSP1 cannot reduce membrane-associated lipid radicals, and the ferroptotic brake is mechanistically compromised [PKB: WS2-PA-Transduction-gpx4-protection-against-ferroptosis-P2]. This section argues that these two chains converge, in a specific patient population, to produce a compounding vulnerability that the net clinical efficacy data obscure rather than resolve.

The Dual-Action Architecture

Statins act simultaneously on two determinants of plaque fate. Their LDL-lowering effect reduces the circulating substrate for oxLDL formation, slows foam cell recruitment, and—over years—reduces incident plaque formation and the growth of early lesions. This benefit is documented with high-quality evidence and is not contested here [19].

INTERPRETATION: The same enzymatic inhibition that restricts LDL production also restricts CoQ10 production, because both derive from the shared mevalonate intermediate farnesyl pyrophosphate. The pharmacological intervention is not selective between these two downstream outputs. Whether the mevalonate flux diverted from CoQ10 synthesis is clinically trivial or meaningful is a quantitative question; the biochemical coupling is structural and unavoidable.

HYPOTHESIS: In patients with advanced plaques already harboring intraplaque hemorrhage, this dual action creates an asymmetric risk profile. The LDL-lowering benefit operates primarily on plaque formation—a process relevant over years to decades and most protective for early or intermediate lesions. The CoQ10-mediated ferroptotic vulnerability operates on plaque stability—a process relevant over hours to weeks in lesions already structured for rupture. For patients with established, hemorrhage-laden plaques, the temporal and anatomical mismatch between these two effects may matter clinically in ways that aggregate trial endpoints cannot detect.

Why This Population Is Specifically Vulnerable

The ferroptotic niche described in Section 4 is not uniformly distributed across the atherosclerotic burden. It is concentrated in lesions with intraplaque hemorrhage, where catalytic iron from erythrocyte lysis accumulates alongside oxLDL-loaded macrophages and structurally critical VSMCs [22]. In this microenvironment, the FSP1-CoQ10 axis represents one of the few remaining antioxidant defenses capable of interrupting lipid radical chain propagation at the membrane level, distinct from the cytosolic GPX4-glutathione system [PKB: WS2-PA-Transduction-gpx4-protection-against-ferroptosis-P2].

HYPOTHESIS: Statin-induced reduction in CoQ10 availability, superimposed on a plaque microenvironment already consuming antioxidant capacity, may lower the ferroptotic threshold for plaque-resident VSMCs and macrophages below what the glutathione system alone can compensate. The consequence would be incremental increases in VSMC ferroptosis—reducing fibrous cap collagen synthesis—and macrophage ferroptosis—expanding the necrotic core through oxidized debris resistant to efferocytosis—at precisely the anatomical sites where structural integrity is already marginal.

Addressing the Net Benefit Objection

FACT: The net clinical benefit of statins is undisputed. Across populations, statin therapy reduces major adverse cardiovascular events by approximately 25% per mmol/L reduction in LDL-C, with consistent benefit across risk strata [19]. This section does not contest that figure.

INTERPRETATION: Population-level benefit is compatible with mechanism-level partial offset in a subgroup. If statin therapy simultaneously reduces the rate of new plaque formation while incrementally accelerating instability in the minority of existing lesions that are ferroptotically primed, the aggregate trial result reflects the dominant effect—plaque prevention—while the minority signal is statistically subsumed. Residual cardiovascular risk in optimally treated statin patients—estimated at approximately 70% of baseline risk remaining despite therapy—requires mechanistic explanation. This hypothesis offers one.

The Absent In Vivo Evidence

FACT: No in vivo evidence directly demonstrates that statin-induced CoQ10 depletion accelerates ferroptosis in atherosclerotic plaque tissue in any model system. The mechanistic chain proposed here is assembled from components each supported independently—mevalonate-CoQ10 coupling, FSP1-CoQ10 function, plaque ferroptotic environment, VSMC ferroptotic susceptibility—but their intersection in living plaque has not been experimentally confirmed.

INTERPRETATION: The absence of this evidence reflects the absence of the experiment, not its negative result. The cellular and biochemical components of this hypothesis are individually established; their convergence is the untested proposition. Section 6 proposes the experimental framework through which that proposition could be falsified.

What this section establishes is the logical necessity of treating statin pharmacology as a dual-output intervention in the context of ferroptosis biology. Clinicians prescribing statins appropriately for cardiovascular risk reduction are, by biochemical necessity, simultaneously modulating CoQ10-dependent ferroptotic resistance in every tissue the drug reaches—including, in patients with advanced disease, the plaques whose stability determines survival.

<!-- SECTION:7 -->

7. Conclusion

Statins reduce major adverse cardiovascular events. This benefit is established and is not in dispute. [FACT] The hypothesis advanced here operates at a different level of analysis: statin-mediated inhibition of HMG-CoA reductase depletes coenzyme Q10 (CoQ10) as an obligate consequence of mevalonate pathway suppression [FACT; WS5-Synthesis-Mitochondrial-ETC-D1], and this depletion may remove a critical endogenous suppressor of ferroptosis within the atherosclerotic plaque, creating a paradoxical vulnerability in the tissue statins are intended to stabilize. [HYPOTHESIS]

The mechanistic chain rests on three individually established observations whose integration constitutes the core hypothesis. First, statins deplete CoQ10 by inhibiting the shared upstream pathway governing both cholesterol and ubiquinone biosynthesis. [FACT; WS5-Synthesis-Mitochondrial-ETC-D1] Second, reduced CoQ10 (ubiquinol) functions as a potent chain-breaking antioxidant in lipid bilayers, directly preventing the lipid peroxidation that defines ferroptotic cell death. [FACT; WS4-TRANSDUCTION-2-Biological-Coq10Ubiquinol; WS2-PA-Transduction-ferroptosis-P2] The FSP1-CoQ10 axis operates as a GPX4-independent ferroptosis suppression pathway. [FACT — peer-reviewed literature] Third, ferroptotic death of lipid-laden macrophages within the necrotic core is associated with plaque destabilization through necrotic core expansion and impaired efferocytosis. [INTERPRETATION — preclinical evidence] The convergence of these three observations into a single compounding mechanism—wherein a drug intended to stabilize plaque simultaneously lowers a ferroptotic threshold within it—has not been directly tested and represents the central proposition of this paper. [HYPOTHESIS]

This framing yields a specific, testable clinical implication. If intra-plaque CoQ10 depletion lowers the ferroptotic threshold in foam cells, then CoQ10 co-supplementation may partially restore that threshold and contribute to plaque stabilization through a mechanism independent of lipid lowering. Whether the circulating CoQ10 reductions documented with statin therapy—reported in the range of 16% to 54% depending on dose and duration [17]—translate to biologically meaningful depletion within the plaque microenvironment remains an open and empirically answerable question.

Residual cardiovascular risk after statin therapy is real and incompletely explained. [FACT; WS3-RP-Regulation-statin-therapy-D1] The predictions generated by this hypothesis—testable in existing biobank samples, preclinical ferroptosis models, and prospective supplementation trials as outlined in Section 6—offer a mechanistically coherent candidate explanation that warrants rigorous investigation.

References

  1. Bentinger M, Tekle M, Dallner G. Coenzyme Q--biosynthesis and functions. Biochemical and biophysical research communications. 2010;396(1):74-9. doi:10.1016/j.bbrc.2010.02.147
  2. Aaseth J, Alexander J, Alehagen U. Coenzyme Q(10) supplementation - In ageing and disease. Mechanisms of ageing and development. 2021;197:111521. doi:10.1016/j.mad.2021.111521
  3. Gasmi A, Bjørklund G, Mujawdiya PK, Semenova Y, Piscopo S, Peana M. Coenzyme Q(10) in aging and disease. Critical reviews in food science and nutrition. 2024;64(12):3907-3919. doi:10.1080/10408398.2022.2137724
  4. Roeck BF, Lotfipour Nasudivar S, Vorndran MRH, Schueller L, Yapici FI, Rübsam M, et al. Ferroptosis spreads to neighboring cells via plasma membrane contacts. Nature communications. 2025;16(1):2951. doi:10.1038/s41467-025-58175-w
  5. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arteriosclerosis, thrombosis, and vascular biology. 2010;30(7):1347-53. doi:10.1161/ATVBAHA.110.206433
  6. Karbakhsh Ravari F, Ghasemi Gorji M, Rafiei A. From iron-driven cell death to clot formation: The emerging role of ferroptosis in thrombogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025;189:118328. doi:10.1016/j.biopha.2025.118328
  7. Cao J, Chen X, Chen L, Lu Y, Wu Y, Deng A, et al. DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target. Redox biology. 2025;85:103788. doi:10.1016/j.redox.2025.103788
  8. Xie LH, Fefelova N, Pamarthi SH, Gwathmey JK. Molecular Mechanisms of Ferroptosis and Relevance to Cardiovascular Disease. Cells. 2022;11(17). doi:10.3390/cells11172726
  9. Chen Y, Yi X, Huo B, He Y, Guo X, Zhang Z, et al. BRD4770 functions as a novel ferroptosis inhibitor to protect against aortic dissection. Pharmacological research. 2022;177:106122. doi:10.1016/j.phrs.2022.106122
  10. Stoyanovsky DA, Tyurina YY, Shrivastava I, Bahar I, Tyurin VA, Protchenko O, et al. Iron catalysis of lipid peroxidation in ferroptosis: Regulated enzymatic or random free radical reaction?. Free radical biology & medicine. 2019;133:153-161. doi:10.1016/j.freeradbiomed.2018.09.008
  11. Iglesias Garriz I, Rodríguez García MA, Delgado Fernández S, Garrote Coloma C, Sastre Ibarretxe M, Corral Fernández F. [Doppler tissue imaging of the mitral annulus in patients with left ventricular systolic dysfunction. Assessment of diastolic function]. Revista espanola de cardiologia. 2000;53(9):1195-200.
  12. Ye Y, Chen A, Li L, Liang Q, Wang S, Dong Q, et al. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification. Kidney international. 2022;102(6):1259-1275. doi:10.1016/j.kint.2022.07.034
  13. Zhang H, Zhou S, Sun M, Hua M, Liu Z, Mu G, et al. Ferroptosis of Endothelial Cells in Vascular Diseases. Nutrients. 2022;14(21). doi:10.3390/nu14214506
  14. Yu S, Pang Z, Fang H, Liu C. Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target. Molecular biomedicine. 2026;7(1). doi:10.1186/s43556-026-00420-9
  15. Jacob M, Chappell D, Rehm M. Clinical update: perioperative fluid management. Lancet (London, England). 2007;369(9578):1984-1986. doi:10.1016/S0140-6736(07)60926-X
  16. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England). 2010;376(9753):1670-81. doi:10.1016/S0140-6736(10)61350-5
  17. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7 Suppl:S168-74. doi:10.1016/j.mito.2007.03.002
  18. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231-7. doi:10.1016/j.jacc.2007.02.049
  19. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al.. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi:10.1016/S0140-6736(10)61350-5
  20. Li C, Liu R, Xiong Z, Bao X, Liang S, Zeng H, et al.. Ferroptosis: a potential target for the treatment of atherosclerosis. Acta Biochim Biophys Sin (Shanghai). 2024;56(3):331-344. doi:10.3724/abbs.2024016
  21. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al.. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693-698. doi:10.1038/s41586-019-1707-0
  22. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al.. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349(24):2316-25. doi:10.1056/NEJMoa035655
  23. Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol. 2003;16(3):267-72. doi:10.1034/j.1600-0854.2003.8042.x
  24. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al.. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693-698. doi:10.1038/s41586-019-1707-0
  25. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al.. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688-692. doi:10.1038/s41586-019-1705-2
  26. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al.. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33(3):226-9. doi:10.1002/j.1552-4604.1993.tb03948.x
  27. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7 Suppl:S168-74. doi:10.1016/j.mito.2007.03.002